Brief introduction of Beijing Peking University Weiming Bioengineering Group Co., Ltd.

Beijing Peking University Weiming Bioengineering Group Co., Ltd. is one of the three major industrial groups in Peking University, mainly engaged in the development of bio-industry and the establishment of bio-economic system, with emphasis on investing in biomedicine, bio-agriculture and bio-service industry. After more than ten years' efforts, the company has developed into a leading enterprise in modern biological industry in China and one of the enterprise groups with the most international competitive potential in China.

Beijing Peking University Weiming Bioengineering Group Co., Ltd. now has three bases: Beijing Peking University Bio-City, Xiamen Peking University Bio-Park and Guangzhou Liuxiwan Bio-Port. More than ten holding subsidiaries: Beijing Kexing Biological Products Co., Ltd., Xiamen Beidadao Biological Engineering Co., Ltd., Guangzhou Peking University Weiming Biotechnology Co., Ltd., Weiming Rentian Chinese Medicine Co., Ltd. and Beijing Weiming Kaituo Agricultural Biotechnology Co., Ltd. ..

The main products operated by Beijing Peking University Weiming Bioengineering Group Co., Ltd. are: mouse nerve growth factor for injection (Njingfu &; Reg Norrback & ampreg), inactivated hepatitis A vaccine (Ailaifu &; Reg Healthy Living & ampreg), Hepatitis A and Hepatitis B Combined Vaccine (Bellevue &; Regbilive & Tman; Ampreg), influenza split vaccine (Anlefutman influenza & Reg), human avian influenza vaccine (panflu &; Reg), influenza A vaccine H1N1(Panerlaifu.1Panflu.1&; reg)。 The group now has a relatively complete R&D system: biopharmaceutical research center, vaccine research center, national crop molecular design center, bio-intelligence research center, bio-economic research center and other institutions, as well as a number of R&D platforms and a group of outstanding R&D talents. Mainly carry out research on bio-economy, biopharmaceuticals, human vaccines, modern Chinese medicine, bio-agriculture, biomass energy, bio-intelligence technology, etc., and achieved a series of major breakthroughs: successfully developed and produced the world's first nerve trauma treatment drug-nerve growth factor, successfully developed the world's first inactivated SARS virus vaccine and China's first human avian influenza vaccine, and in August 2009, reg), The intelligent sterile molecule design technology that will trigger the third agricultural revolution will initially establish the world's first "bio-economic incubator (efficient research and development system of new drugs)", create a bio-economic theoretical system, initially construct a bio-economic system and an economic bio-restructuring model, and initially explore the development ideas of bio-industry suitable for China's national conditions.

Beijing Peking University Weiming Bioengineering Group Co., Ltd. reorganized its enterprises and integrated its industries through government guidance and market mechanism, and established five industrial groups, namely vaccine group, traditional Chinese medicine group, biopharmaceutical group, modern agriculture group and biological service group, based on the existing core enterprises of the group. By building the world's first bio-economic system (including three systems of industry, R&D and finance), we can achieve the goal of building leading enterprises, cultivating excellent teams and triggering industrial revolution, and finally turn Peking University Weiming Group into a bio-economic group.